Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology will deliver a late-breaking oral presentation of Phase 1 MICVO monotherapy data in previously treated recurrent/metastatic head and neck squamous cell carcinoma at the EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026. The company will also present two preclinical posters on MICVO, an antibody-drug conjugate targeting extradomain-B of fibronectin, which holds FDA Fast Track Designation for R/M HNSCC.
Key figures
- Drug Name
- micvotabart pelidotin (MICVO, formerly PYX-201)
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.